-
Ab177891-10mgNI-0701 (anti-CCL5) is a antibody tageting CCL5.
-
Ab177891-1mgNI-0701 (anti-CCL5) is a antibody tageting CCL5.
-
Ab177891-5mgNI-0701 (anti-CCL5) is a antibody tageting CCL5.
-
Ab177882-100μgNimacimab (anti-CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases.
-
Ab177882-10mgNimacimab (anti-CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases.
-
Ab177882-1mgNimacimab (anti-CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases.
-
Ab177882-5mgNimacimab (anti-CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases.
-
Ab177919-100μgOS2966 (anti-ITGB1) is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity.
-
Ab177919-10mgOS2966 (anti-ITGB1) is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity.
-
Ab177919-1mgOS2966 (anti-ITGB1) is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity.
-
Ab177919-5mgOS2966 (anti-ITGB1) is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity.
-
Ab170580-100μgOzuriftamab (anti-ROR2) is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg